How can ASX investors buy the US stock the WHOLE world is talking about?

Want to know how to buy the international stock du jour from the comfort of the ASX? Read on!

| More on:
Shot of two young scientists using a laptop in a laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ASX investor or not, chances are you might have heard of the 'wonderdrug' Ozempic. Hailed for its benefits for patients with diabetes, Ozempic's potential applications also extend to obesity treatment and weight loss.

As such, this drug's potential benefits have already had a big impact on the ASX, with companies that potentially compete with its applications, such as ResMed Inc (ASX: RMD) and CSL Limited (ASX: CSL), recently being sold off.

As such, many ASX investors might be hoping to invest in Ozempic. Or more specifically, in Novo Nordisk A/S (CPH: NOVO-B)(NYSE: NVO) shares. Novo Nordisk is the pharmaceutical company that produces Ozempic.

But there's a problem for ASX investors. Novo Nordisk shares are nowhere to be found on the ASX.

The company is Danish in origin. So it will come as no surprise to hear that Novo Nordisk's primary public listing is on the Nasdaq Copenhagen Stock Exchange. Most ASX investors don't even have access to this stock market, with only a handful of select brokerage firms offering access.

However, Novo Nordisk does have a secondary listing on the US markets. Specifically on the New York Stock Exchange (NYSE). So ASX investors with the desire and access to invest in US shares can buy Novo Nordisk stock under the ticker code 'NYSE: NVO' if they so wish.

Want to buy this popular US stock? Try an ASX healthcare ETF

But there is another way to invest in this exciting opportunity on the ASX. It's by using exchange-traded funds (ETFs). Now since Novo Nordisk shares can be found on the NYSE, one would be forgiven for assuming that a simple US index fund might do the job.

But sadly, Novo Nordisk shares aren't a constituent of either the iShares S&P 500 ETF (ASX: IVV) or the BetaShares NASDAQ 100 ETF (ASX: NDQ). Those are two of the most popular US index funds listed on the ASX, but neither holds this company.

But don't despair. There are still ASX ETFs that will allow one to indirectly invest in the Ozempic producer. ASX healthcare ETFs, to be precise.

As we covered back in September, the VanEck Global Healthcare Leaders ETF (ASX: HLTH) is one such fund. Holding 51 healthcare stocks from around the world, this ETF is designed to allow ASX investors access to a range of healthcare companies that aren't listed in Australia. As of 1 November, Novo Nordisk was one such company, commanding a portfolio weighting in HLTH's portfolio of 2.17%.

The BetaShares Global Healthcare ETF (ASX: DRUG) is another similar fund with 69 underlying holdings. However, Novo Nordisk's holdings within DRUG are more than double that of HLTH, with a weighting here of 5.7%.

Finally, let's talk about the iShares Global Healthcare ETF (ASX: IXJ). This fund operates on a larger scale than those other two healthcare ETFs, with approximately 115 holdings. Despite this, IXJ still offers ASX investors a 4.78% weighted exposure to the Ozempic maker's shares in the portfolio.

So if you're desperate to invest in Ozempic through its maker Novo Nordisk, there are certainly a few options on the ASX to consider today. Even if you don't wish to buy the US or Danish-listed shares directly.

Motley Fool contributor Sebastian Bowen has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended BetaShares Nasdaq 100 ETF, CSL, and ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Novo Nordisk. The Motley Fool Australia has positions in and has recommended BetaShares Nasdaq 100 ETF and ResMed. The Motley Fool Australia has recommended CSL and iShares S&P 500 ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Telix Pharmaceuticals share price sinks on unexpected Nasdaq news

ASX 200 investors are bidding down the Telix Pharmaceuticals share price today. But why?

Read more »

Health workers shake hands and congratulate each other on good news.
Healthcare Shares

This ASX 200 healthcare stock is up 48% in a year, but one director is still buying!

A director of this ASX 200 healthcare company has just lifted his personal stake by 50%.

Read more »

A man and woman in an office look at a laptop and discuss investing, budget strategies or other financial concepts
Healthcare Shares

Why this broker just upgraded Telix shares to a buy rating

Bell Potter thinks a recent pullback has created a buying opportunity.

Read more »

A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.
Healthcare Shares

Sigma share price dives 6% on Chemist Warehouse merger hurdle

The proposed merger faces ACCC concerns.

Read more »

A person wrapped in warm clothing with head, eyes and face covered by a hat, glasses and a scarf is coated in a layer of snow and ice. representing Strike Energy's trading halt today
Healthcare Shares

Why is the Telix Pharmaceuticals share price frozen today?

Telix Pharmaceuticals shares won’t be moving today.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

3 ASX 300 healthcare stocks 'well positioned to outperform'

Wilsons thinks the healthcare sector could be about to outperform the broader market.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

CSL shares can 'absolutely' head to $500: ASX expert

This expert reckons it's foolish to bet against CSL...

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

2 ASX biotech shares that could be the next Telix Pharmaceuticals

These ASX biotech shares could become the next Telix Pharmaceuticals. But how?

Read more »